1. Introduction {#s0005}
===============

Compared with other antipsychotic drugs, clozapine is the most effective pharmacotherapy for schizophrenia; its use is generally restricted to treatment-resistant patients because of safety risks, notably agranulocytosis, myocarditis, and severe constipation ([@bb0005]). Surveys have identified similar ([@bb0065]) or somewhat higher ([@bb0010]) rates of clozapine use in Maori compared to Europeans, the two dominant ethnic groups in New Zealand. Ethnicity has been shown to influence clozapine pharmacokinetics in some settings; for example, compared with Caucasians, lower daily clozapine doses are needed to achieve comparable blood levels in Asian ([@bb0060]) and Mexican patients ([@bb0035]). There are no published data on the pharmacokinetics of clozapine in Maori, although mean daily clozapine doses were similar in Maori and European patients in a retrospective cross-sectional survey ([@bb0015]). Effective treatment of schizophrenia in Maori is of particular importance given its apparently higher prevalence compared with the European population ([@bb0045]). This study used data from a bioequivalence trial of two clozapine formulations ([@bb0030]) in order to compare the pharmacokinetics of clozapine and its active metabolite norclozapine in Maori and European patients.

2. Materials and Methods {#s0010}
========================

A detailed description of the bioequivalence study, including sample size calculation, is provided elsewhere ([@bb0030]). In brief, the study enrolled 30 male and female subjects, aged 18 to 55 years, established on stable doses of clozapine for at least 3 months. Subjects were required to have a body mass index (BMI) between 18 and 35 kg/m^2^, and be in good health. Clozapine was prescribed in multiples of 50 mg, taken as a single evening dose. Subjects provided written informed consent prior to participation. The study conformed to standards indicated by the Declaration of Helsinki; approval was provided by the New Zealand Multi-Region Ethics Committee (MEC/10/09/094). The study design involved an 11-day dosing period with one formulation, tablet or suspension, with pharmacokinetic blood sampling under fasting and fed conditions on days 10 and 11, respectively. Study subjects were then switched to the alternate formulation from days 12--22, with repeated pharmacokinetic sampling on days 21 and 22. The order in which formulations were administered was based on a computer-generated random code. The formulations were found to be bioequivalent under fasting and fed conditions ([@bb0030]). This report describes the pharmacokinetics of the tablet formulation (Clozaril®, Novartis) in Maori and European participants.

On Days 10 and 21, subjects were admitted to the study clinic at least 10 h prior to drug administration, and were discharged after the final blood draw in the morning of Days 12 and 23. Clozapine was administered after an 8-hour fast on Days 10 and 21, and was dosed under fed conditions on Days 11 and 22 after consumption of a standardized high-fat meal ([@bb0025]). All clozapine doses were administered with 240 mL water. There was no washout period between the two treatment periods. On Days 10, 11, 21 and 22, blood samples were collected at baseline and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 14, 16, 20 and 24 h after dosing. Following centrifugation, plasma samples were stored in polypropylene tubes at 70 °C until assayed using validated liquid chromatography with tandem mass spectrometry methods. Clozapine was assayed using a previously reported method ([@bb0030]). The norclozapine assay was similar although a different internal standard (*N*-desmethylmirtazapine) was used.

Pharmacokinetic parameters, calculated using standard non-compartmental methods, included maximum plasma concentration (C~max~), area under the plasma concentration--time curve from time 0 to the end of the dosing interval (AUC~0-τ~), time to C~max~ (t~max~), and minimum concentration (C~min~). Because patients were taking different daily doses of clozapine, all clozapine and norclozapine plasma concentrations and pharmacokinetic data were normalised to a dose of 100 mg.

Safety was monitored by assessing adverse events, laboratory test results, vital signs (heart rate and blood pressure), and electrocardiograms (ECGs).

Pharmacokinetic parameters were compared using unpaired *t*-tests or, as necessary, the Mann-Whitney *U* test, a non-parametric equivalent. Safety data were analysed using summary statistics. The sample size for the study was pragmatic. Post-hoc assessment of statistical power indicates that the study had at least 80% power to detect a 40% difference in AUC and a 30% difference in C~max~, based on fasted pharmacokinetic parameters.

3. Results {#s0015}
==========

3.1. Subjects {#s0020}
-------------

Of 30 subjects in the original bioequivalence study, two of other ethnic origins were excluded from the present comparison of 16 European (13 male, 3 female) with 12 Maori participants (10 male, 2 female), see [Table 1](#t0005){ref-type="table"}. Maori ethnicity was determined according to the New Zealand Census procedure (2001), and confirmed by participants identifying at least one (mean 2.9, range 1--4) Maori grandparent. Neither age nor BMI differed statistically between the two groups (European \[mean ± standard deviation\] age = 38.0 ± 9.0 years, BMI = 30.0 ± 5.0 kg/m^2^; Maori age = 37.6 ± 10.4 years, BMI = 32.2 ± 5.2 kg/m^2^). Among European participants there were 6 smokers and 10 nonsmokers, and in Maori, 8 smokers and 4 nonsmokers. The greater proportion of Maori than European smokers (67% vs. 37%) did not reach statistical significance (chi square = 1.31, p = 0.25).Table 1Demographic, prescription and smoking data.Table 1ParticipantEthnicityGenderAge (years)BMI (kg/m^2^)Clozapine mg/dayTobacco cigarettes/dayConcomitant medications1MaoriMale422440020Amitriptyline 25 mg twice daily2MaoriMale4632.510020Lamivudine 100 mg dailyPantoprazole 40 mg daily3MaoriMale42424000[a](#tf0005){ref-type="table-fn"}Omeprazole 20 mg dailyMetformin 850 mg dailyDiclofenac 75 mg PRN4MaoriMale283835016Omeprazole 20 mg dailySodium valproate 1.6 g daily5MaoriMale3031.445015Amisulpride 400 mg twice daily6MaoriMale2833.970010Venlafaxine 150 mg daily7MaoriMale5729.770024Lithium carbonate 1.5 g daily8MaoriFemale46374005Quetiapine 50 mg dailyFluoxetine 20 mg9MaoriMale2733.44000[a](#tf0005){ref-type="table-fn"}Nil10MaoriMale4829.84000[a](#tf0005){ref-type="table-fn"}Risperidone 0.5 tab dailyBenztropine 2 mg daily11MaoriFemale3330.81000[a](#tf0005){ref-type="table-fn"}Quetiapine 50 mg twice dailyLoperamide 2 mg (if required)Propanolol 40 mg twice daily12MaoriMale252460013Nil13EuropeanMale4222.84000[a](#tf0005){ref-type="table-fn"}Citalopram 40 mg dailySimvastatin 10 mg dailyClonazepam 0.5 mg daily14EuropeanMale4024.270020Clonazepam 2 mg dailySimvastatin 20 mg daily15EuropeanMale29245000[a](#tf0005){ref-type="table-fn"}Lithium carbonate 2.5 g dailySimvastatin 40 mg daily16EuropeanMale56283005Omeprazole 20 mg dailyCalcium carbonate 1.25 g daily17EuropeanMale4129.74008Nil18EuropeanFemale4537.86500[a](#tf0005){ref-type="table-fn"}Haloperidol 50 mg i.m. monthlyHaloperidol 5 mg nocte PRNCilazapril1.25 mg dailyPantoprazole 40 mg daily19EuropeanFemale4822.12000[a](#tf0005){ref-type="table-fn"}Levonorgestrel 20 mcg daily20EuropeanMale483760020Chlopromazine 100 mg dailyClonazepam 2 mg dailyLevothyroxine 0.05 mg dailySodium valproate 1.8 g dailyLithium carbonate 1.2 g daily21EuropeanMale29283500[a](#tf0005){ref-type="table-fn"}Nil22EuropeanMale4035.46000[a](#tf0005){ref-type="table-fn"}Sodium valproate 600 mg NocteAmisulpiride 300 mg nocteCitalopram 40 mg daily23EuropeanMale3832.81000[a](#tf0005){ref-type="table-fn"}Omeprazole 20 mg daily24EuropeanMale2927.73500[a](#tf0005){ref-type="table-fn"}Omeprazole 40 mg dailySodium valproate 1.4 g dailySimvastatin 20 mg daily25EuropeanMale2632.44000[a](#tf0005){ref-type="table-fn"}Nil26EuropeanFemale3932.53500[a](#tf0005){ref-type="table-fn"}Metoprolol 95 mg dailyOmeprazole 20 mg dailyAtorvastatin 30 mg daily27EuropeanMale3434.750010Amisulpride 600 mg twice dailyLithium carbonate 1.2 g daily28EuropeanMale2432.25005Fluoxetine 40 mg daily[^1]

3.2. Pharmacokinetics {#s0025}
---------------------

Steady-state clozapine and norclozapine pharmacokinetic parameters are shown in [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}. There were no statistically significant differences between Maori and European groups for any pharmacokinetic parameter, under both fed and fasted conditions. A 2-way analysis of variance indicated no significant effects of smoking, ethnicity, or their interaction on clozapine dose or pharmacokinetic parameters (data not shown).Table 2Mean (s.d.) steady state clozapine pharmacokinetic parameters by ethnic group.Table 2Maori (n = 12)European (n = 16)t[a](#tf0010){ref-type="table-fn"}; pFastedAUC~0 − τ~(ng·h/mL)3257 (845)3056 (1311)0.46; 0.64C~max~ (ng/mL)266 (55.8)260 (81.2)0.24; 0.81C~min~ (ng/mL)71.4 (23.9)68.6 (39.1)0.20; 0.84t~max~ (h)2.5[b](#tf0015){ref-type="table-fn"}2[b](#tf0015){ref-type="table-fn"}64.5[c](#tf0020){ref-type="table-fn"}; 0.14  FedAUC~0 − τ~(ng·h/mL)3068(598)2890 (1237)0.46; 0.65C~max~ (ng/mL)214 (47.2)211 (70.2)0.11; 0.91C~min~ (ng/mL)69.1 (21.2)66.5 (39.1)0.21; 0.84t~max~ (h)5[b](#tf0015){ref-type="table-fn"}4[b](#tf0015){ref-type="table-fn"}61.0[c](#tf0020){ref-type="table-fn"}; 0.11[^2][^3][^4]Table 3Mean (s.d.) steady state302 norclozapine pharmacokinetic parameters by ethnic group.Table 3MaoriEuropeant[a](#tf0025){ref-type="table-fn"}; pFastedAUC~0 − τ~(ng·h/mL)1736 (622)1722 (884)0.04; 0.97C~max~ (ng/mL)106 (42.4)112 (55.6)0.31; 0.76C~min~ (ng/mL)48.5 (18.3)50.8 (29.6)0.24; 0.81t~max~ (h)2[b](#tf0030){ref-type="table-fn"}2[b](#tf0030){ref-type="table-fn"}85[c](#tf0035){ref-type="table-fn"}; 0.61  FedAUC~0 − τ~(ng·h/mL)1642 (523)1640 (937)0.01; 0.99C~max~ (ng/mL)92.0 (31.3)100 (68.2)0.40; 0.70C~min~ (ng/mL)47.0 (16.0)49.3 (29.4)0.24; 0.81t~max~ (h)5.5[b](#tf0030){ref-type="table-fn"}4.5[b](#tf0030){ref-type="table-fn"}77[c](#tf0035){ref-type="table-fn"}; 0.39[^5][^6][^7]

3.3. Safety {#s0030}
-----------

There were no deaths or serious adverse events during the study. A total of 165 adverse events were reported by 18 subjects while taking clozapine tablets. The most common of these were drowsiness (46 reports), constipation (25 reports), dizziness (23 reports), dry mouth (16 reports), and confusion and blurred vision (15 reports each). All adverse events were of mild to moderate intensity. There were no differences in adverse event reporting between Maori and European groups, and all adverse events had resolved by study completion. There were no findings of note from safety laboratory tests, ECGs or vital signs.

4. Discussion {#s0035}
=============

The main finding of this study is that there are no differences in steady-state clozapine or norclozapine pharmacokinetics, under both fed and fasted conditions, between Maori and NZ European patients. This finding is consistent with an earlier report of similar mean daily clozapine doses in Maori and European patients ([@bb0015]).

Based on the complexity of clozapine metabolism, it was not possible a priori to predict whether Maori and European pharmacokinetic parameters would be similar or different. Cytochrome-P450 (CYP) 1A2 is the predominant enzyme involved in clozapine metabolism, with CYP3A and CYP2C19 also involved ([@bb0040]). Maori have been reported to have higher frequencies of two poor metabolizer alleles for CYP2C19 (\*2 and \*3) compared with Caucasians ([@bb0050]). Because of the substantial effects of environmental factors on CYP1A2 activity, phenotyping may be preferred for assessment of activity in vivo ([@bb0020]). Rates of CYP1A2 poor metabolism vary by ethnic group ([@bb0055]), but there are as yet no published data available regarding Maori.

The limitations of this study include the fact that it was based on a post-hoc analysis of participants enrolled in a bioequivalence study. Although the entire study was adequately statistically powered, analysis by ethnic subgroup was not. Post-hoc estimates indicate the study was adequately powered to detect large (30--40%) differences in pharmacokinetic parameters, and thus subtle differences might be missed. On the other hand, the between group results are remarkably similar, suggesting that the risk of a Type II error is small. A further limitation of this study is that we were unable to control for smoking status or prescription of concomitant medications, both known to potentially affect clozapine metabolism.

In conclusion, the finding of essentially identical clozapine bioavailability in Maori and European subjects suggests that this drug can be dosed in the New Zealand setting without consideration of ethnicity.
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[^1]: Non-smoker or abstinent for least six months.

[^2]: Unpaired *t*-test, df = 26.

[^3]: Median.

[^4]: Mann-Whitney *U* test.
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